# Andrew L Hopkins

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 44 papers | 18,078 citations | 172207 29 h-index | 276539 41 g-index |
| 47 all docs | 47 docs citations | 47 times ranked | 20863 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. Scientific Reports, 2021, 11, 13208. | 1.6 | 24 |
| 2 | Surveying GPCR solubilisation conditions using surface plasmon resonance. Analytical Biochemistry, 2018, 556, 23-34. | 1.1 | 5 |
| 3 | Discovery of New Bromodomain Scaffolds by Biosensor Fragment Screening. ACS Medicinal Chemistry Letters, 2016, 7, 1213-1218. | 1.3 | 18 |
| 4 | The Joint European Compound Library: boosting precompetitive research. Drug Discovery Today, 2015, 20, 181-186. | 3.2 | 59 |
| 5 | Application of RNAi to Genomic Drug Target Validation in Schistosomes. PLoS Neglected Tropical Diseases, 2015, 9, e0003801. | 1.3 | 33 |
| 6 | Surface Plasmon Resonance Analysis of Seven-Transmembrane Receptors. Methods in Enzymology, 2015, 556, 499-525. | 0.4 | 23 |
| 7 | Fragment screening by SPR and advanced application to GPCRs. Progress in Biophysics and Molecular Biology, 2014, 116, 113-123. | 1.4 | 63 |
| 8 | Validity of Ligand Efficiency Metrics. ACS Medicinal Chemistry Letters, 2014, 5, 616-618. | 1.3 | 112 |
| 9 | The role of ligand efficiency metrics in drug discovery. Nature Reviews Drug Discovery, 2014, 13, 105-121. | 21.5 | 849 |
| 10 | Discovery of Î²2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor. ACS Medicinal Chemistry Letters, 2013, 4, 1005-1010. | 1.3 | 65 |
| 11 | Whole Organism High-Content Screening by Label-Free, Image-Based Bayesian Classification for Parasitic Diseases. PLoS Neglected Tropical Diseases, 2012, 6, e1762. | 1.3 | 93 |
| 12 | Automated design of ligands to polypharmacological profiles. Nature, 2012, 492, 215-220. | 13.7 | 698 |
| 13 | Quantifying the chemical beauty of drugs. Nature Chemistry, 2012, 4, 90-98. | 6.6 | 1,194 |
| 14 | Screening for GPCR Ligands Using Surface Plasmon Resonance. ACS Medicinal Chemistry Letters, 2011, 2, 549-554. | 1.3 | 81 |
| 15 | Emerging role of surface plasmon resonance in fragment-based drug discovery. Future Medicinal Chemistry, 2011, 3, 1809-1820. | 1.1 | 53 |
| 16 | Rapid Analysis of Pharmacology for Infectious Diseases. Current Topics in Medicinal Chemistry, 2011, 11, 1292-1300. | 1.0 | 15 |
| 17 | Editorial [Hot Topic: Progress in Neglected Disease Drug Discovery (Guest Editors: Andrew L. Hopkins) Tj ETQq1 1 0.784314 rgBT /Ov | 1.0 | 6 |
| 18 | Know your chemical space. Nature Chemical Biology, 2010, 6, 482-483. | 3.9 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | An Ontology for Description of Drug Discovery Investigations. Journal of Integrative Bioinformatics, 2010, 7, . | 1.0 | 13 |
| 20 | Fragment Screening by Surface Plasmon Resonance. ACS Medicinal Chemistry Letters, 2010, 1, 44-48. | 1.3 | 134 |
| 21 | An ontology for description of drug discovery investigations. Journal of Integrative Bioinformatics, 2010, 7, . | 1.0 | 22 |
| 22 | Predicting promiscuity. Nature, 2009, 462, 167-168. | 13.7 | 165 |
| 23 | A crowdsourcing evaluation of the NIH chemical probes. Nature Chemical Biology, 2009, 5, 441-447. | 3.9 | 111 |
| 24 | Network pharmacology: the next paradigm in drug discovery. Nature Chemical Biology, 2008, 4, 682-690. | 3.9 | 3,165 |
| 25 | Genomic-scale prioritization of drug targets: the TDR Targets database. Nature Reviews Drug Discovery, 2008, 7, 900-907. | 21.5 | 282 |
| 26 | Pharmacological Space. , 2008, , 521-532. | | 4 |
| 27 | Pharmacological Space. , 2008, , 395-408. | | 0 |
| 28 | Mission possible. Nature, 2007, 449, 166-169. | 13.7 | 41 |
| 29 | Network pharmacology. Nature Biotechnology, 2007, 25, 1110-1111. | 9.4 | 933 |
| 30 | Knowledge and Intelligence in Drug Design. Annual Reports in Medicinal Chemistry, 2006, , 425-437. | 0.5 | 7 |
| 31 | Global mapping of pharmacological space. Nature Biotechnology, 2006, 24, 805-815. | 9.4 | 776 |
| 32 | How many drug targets are there?. Nature Reviews Drug Discovery, 2006, 5, 993-996. | 21.5 | 3,073 |
| 33 | Can we rationally design promiscuous drugs?. Current Opinion in Structural Biology, 2006, 16, 127-136. | 2.6 | 472 |
| 34 | Structural Bioinformatics in Drug Discovery. Methods of Biochemical Analysis, 2005, 44, 477-497. | 0.2 | 9 |
| 35 | Ligand efficiency: a useful metric for lead selection. Drug Discovery Today, 2004, 9, 430-431. | 3.2 | 1,687 |
| 36 | Design of Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 2.. Journal of Medicinal Chemistry, 2004, 47, 5923-5936. | 2.9 | 61 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Design of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 1.. Journal of Medicinal Chemistry, 2004, 47, 5912-5922. | 2.9 | 87 |
| 38 | Protein kinase drugs â€“ optimism doesn't wait on facts â–¾. Drug Discovery Today, 2002, 7, 801-802. | 3.2 | 15 |
| 39 | The druggable genome. Nature Reviews Drug Discovery, 2002, 1, 727-730. | 21.5 | 2,918 |
| 40 | Design of MKC-442 (Emivirine) Analogues with Improved Activity Against Drug-Resistant HIV Mutants. Journal of Medicinal Chemistry, 1999, 42, 4500-4505. | 2.9 | 130 |
| 41 | Crystallographic Analysis of the Binding Modes of Thiazoloisoindolinone Non-Nucleoside Inhibitors to HIV-1 Reverse Transcriptase and Comparison with Modeling Studies. Journal of Medicinal Chemistry, 1999, 42, 3845-3851. | 2.9 | 42 |
| 42 | Crystal Structures of HIV-1 Reverse Transcriptase in Complex with Carboxanilide Derivativesâ€‚â€¡. Biochemistry, 1998, 37, 14394-14403. | 1.2 | 97 |
| 43 | 3â€²-Azido-3â€²-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9518-9523. | 3.3 | 71 |
| 44 | Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors. Journal of Medicinal Chemistry, 1996, 39, 1589-1600. | 2.9 | 353 |